The placental transfer of alcuronium was studied in twelve patients undergoing elective or emergency caesarean section. Umbilical cord vein and maternal plasma was analysed for alcuronium at dose-delivery time intervals ranging from 5 to 10.5 minutes. The mean umbilical vein concentration of the relaxant was 0.41 ± 0.18 (SD) Jig/ml, and the mean foetal/maternal concentration ratio was 0.26 ± 0.11. A positive correlation between foetal and maternal concentrations of alcuronium was demonstrated. Although alcuronium appears to cross the placenta rapidly and in reasonably high concentration, no apparent adverse effects on the neonates was evident as judged by measurement of Apgar scores.
to cross the placental barrier than other nondepolarizing relaxants, but no reasons were given to support their suggestion. The purpose of this study was to re-investigate the placental transfer of alcuronium, using a modification of the spectroflurometric method, originally developed by Kersten and co-workers. METHOD Twelve patients undergoing elective or emergency caesarean section were studied. Particulars of the patients are summarized in Table 1 . All patients were premedicated with Mist. magnesium trisilicate (BP) 15 ml within one hour of operation. Patients were placed in a position of left uterine displacement and after pre-oxygenation, anaesthesia was induced with thiopentone, followed by succinylcholine. Cricoid pressure was applied, the trachea was intubated and anaesthesia was maintained with 500;0 nitrous oxide in oxygen. After induction alcuronium 0.18-0.46 mg/kg was rapidly injected as a bolus dose (see Table 1 for details). At the end of the surgical procedure all patients received atropine and neostigmine to antagonise any residual paralysis. Blood samples were obtained within three minutes after delivery from the placental end of the umbilical vein and at the time of cord clamping from the mother's radial artery. Control samples were collected from other healthy women undergoing normal vaginal delivery and caesarean section under epidural anaesthesia with both lignocaine and bupivacaine and from the umbilical veins of the placenta following delivery. These patients did not receive alcuronium or other muscle relaxants. All blood samples were then centrifuged and the plasma separated and stored at -20 QC until assayed. Preliminary experiments indicated that alcuronium was stable upon storage using this procedure.
The concentrations of alcuronium in plasma were measured by the procedure described by Walker et al. 4 The calibration curve relating alcuronium concentration of fluorescence was linear in the range 0.05-3 ug/ml. All analyses were done in duplicate.
RESULTS
Alcuronium was not detected in any of the control material or cord samples, but was found in all samples obtained at caesarean section under general anaesthesia. The results obtained are given in Table 2 . The mean umbilical vein level of the relaxant was 0.41 ± 0.18 (SO) ug/ml with a range of 0.06 to 0.65 ug/ml. The average umbilical vein to maternal arterial concentration ratio was 0.26 ± 0.11 (SO), ranging from 0.045 to 0.398. There was a weak positive correlation between the cord/maternal concentration ratios and the time interval between injection of the alcuronium and delivery of the infant, which varied from 5 to 10.5 minutes (r=0.39, P < 0.05) ( Figure 1 ). When the umbilical cord levels were plotted against the maternal levels, the cord levels in one group of patients (n = 8) were found to be significantly higher than in the others (n = 4) P < 0.05) ( Figure 2 ). These two groups of patients were arbitrarily designated as group 1 and group 2 respectively. There was a strong positive correlation between umbilical cord and maternal levels within each group. Combination of data from both groups still gave a positive correlation between these variables (r = 0.63). The average dose-delivery time of group 1 (8.10 ± 1.85 minutes) was higher than that of group 2 (6.20 ± 1.13 minutes) (P < 0.05).
The Apgar scores of the delivered infants are shown in Table 2 . All scores were ten after ten minutes from delivery. The foetal pH, Pa02 and PaC02 values were within the normal ranges (Table 3) . Muscle relaxants are quaternary ammonium compounds, which are completely ionized at normal physiological pH. When they were first introduced to obstetric practice, they were expected not to pass the lipoid placental barrier. In fact, no appreciable neuromuscular block has been detected in newborn infants with normal clinical doses. 5 However, recent studies have indicated that muscle relaxants Anaesthesia and Intensive Care, Vol. IX, No. 2, May, 1981 such as pancuronium,6-9 succinylcholine lO and dimethyltubocurarine!! do cross the placenta rapidly. Detectable amounts of !4C-dimethyltubocurarine were found in umbilical blood two minutes after injection into the mother.u A study of the placental transfer of !4C-succinylcholine hydroiodide in monkeys revealed peak concentrations were achieved in the foetus 5 to 10 minutes after administration to the mother. 10 Spiers and Sim 6 have also reported that pancuronium could be found in foetal urine after maternal injection, even when the injection-delivery interval was as short as 5 minutes. More recently, the cord/maternal vein concentration ratio of pancuronium has been observed to increase with prolongation of the injection-delivery interval. 7-9
Even though alcuronium is one of the nondepolarizing muscle relaxants used in caesarean section, information of its placental transfer is scanty. In 1969, Thomas et al.!
reported that small quantities of alcuronium could be detected in the cord blood of 12 infants out of a total of 19 patients. Alcuronium was found to pass the placental barrier rapidly, since detectable amounts were noted in the umbilical cord blood three minutes after injection to the mother. Another feature commented on by these authors was that shortly after injection, the cord plasma concentration of alcuronium was as high as those concentrations determined after longer intervals between administration and delivery. In this present study, the ratio of cord/maternal levels was found to rise rapidly five to seven minutes after administration to the mother (Figure 1 ). Our observations can then be regarded as being in agreement with the findings of Thomas and co-workers.! When the umbilical cord levels were plotted against maternal levels, cord levels in one group of patients were found to be significantly higher than in the others (p < 0.05) ( Figure 2 ). In addition, a strong positive correlation between umbilical cord and maternal levels was found within each group and for the combined groups. Obviously maternal levels were high initially after intravenous injection. If the foetal levels were proportional to the maternal levels, the foetal levels would therefore also be initially high. This further supports the contrast to our findings, Thomas et al. could not detect any correlation between foetal cord and maternal plasma concentrations. In our study a spectrofluorometric method of analysis was used which is likely to be more accurate for alcuronium than the bio-assay techniques used in the earlier investigation. This might help to explain the discrepancies in the results of these two studies.
Efforts have been taken to rationalise the observed difference between group 1 and group 2 patients. An obvious explanation might be that some of the samples were collected from cord venous and others from cord arterial blood. Every effort was made to identify a placental vein before taking the blood which was taken from the vein just as it enters the cord. The pH of all our samples was within the range of cord venous blood (Table 3) .
Another possible explanation of this observation is that there may be some delay for the relaxant to diffuse across the placenta before appreciable levels occur in the umbilical vein. The average dose-delivery intervals of group 1 patients (S.1O±1.S5 minutes) are longer than those in group 2 (6.20 ± 1.13 minutes) (p < 0.05). After a lag phase, considered to be a rate-determining step, the foetal concentration increases rapidly. Nevertheless proportionality between the cord and maternal levels was obtained in five minutes after drug administration to the mother.
Protein binding is another factor which may alter the transfer of drug across the placenta. Salicylates which are almost completely ionized at physiological pH cross the placental membrane rapidly Y A case report has indicated that the neonatallmaternal plasma concentration ratio was as high as 1.6 at delivery after a mother had taken large daily doses of salicylate throughout her pregnancy. 13 In a follow-up study, these authors found that protein binding of salicylate in neonatal serum was more extensive than in maternal serum, and there was a strong correlation between the neonatal:maternal concentration ratios of salicylate at diffusion equilibrium and the neonatal:maternal albumin concentration ratios.14 They suggested that the rapid transfer of drug might be due to a higher concentration of albumin in the foetus when compared to the mother at delivery as was noted by Cochran.15 The presence of higher concentrations of endogenous binding inhibitors such as lipoprotein and fatty acids in maternal plasma at the end of gestation might also help to create a concentration gradient across the placenta. 16 In the present study, the foetal albumin levels Anaesthesia and intensive Care, Vol. IX, No, 2, May, 1981 were found to be equal to or higher than the maternal levels in all cases with one exception (case 12, Table 2 ). Protein binding information for alcuronium is scarce but the percentage bound to total plasma protein has been reported to be 400/0. Stovner and co-workers l8 tried to relate individual dose requirements of alcuronium to the concentration of each fraction of plasma protein present. They found alcuronium requirement correlated reasonably well with the plasma albumin fraction (r = 0.62). This finding might imply that alcuronium was bound to albumin to an appreciable extent. If this were the case, a correlation between the neonatallmaternal concentration ratio of alcuronium and albumin might then be expected. Such a correlation was not detected in our study overall. However, a correlation was found within group 2 (r = 0.72), but neither the number of patients studied, nor the limited range of dose-delivery interval, allows us to draw any conclusions at this stage. Protein binding of alcuronium in foetal and maternal plasma warrants further investigation.
CLINICAL IMPLICATIONS
As with other muscle relaxants, alcuronium also crosses the placenta quite readily. The drug could be detected in the umbilical cord as soon as five minutes after administration to the mother. The cord/maternal ratios of alcuronium ranged from 0.045 to 0.398 for a dose-delivery time interval of 5-10.5 minutes. These ratios are similar to those noted for pancuronium but they are achieved over a longer period. The dose-delivery intervals for pancuronium ranged from 3 to 40 minutes. 7 ,s While results obtained with dimethyltubocurarine indicate a lower ratio (0.04 to 0.12) obtained within a dose-delivery interval of 2 to 10 minutes. 11 From the results obtained here, the cord plasma concentrations for alcuronium were found to be proportional to the maternal levels. This implies that the exposure of the foetus to alcuronium depends on the maternal concentrations. Increased dosage of the relaxant would give higher maternal levels and result in more drug passage across the placenta. However, no evidence of significant neuromuscular block in infants delivered of mothers by caesarean section with normal clinical doses has been reported.
A recent study comparing succinylcholine and pancuronium as agents used for endotracheal intubation in two groups of patients undergoing caesarean section where both groups also received pancuronium to maintain relaxation, found that use of the latter relaxant as an intubating agent increased dosedelivery time and elevated levels of pancuronium in the umbilical cord. 9 In the light of this finding and of the re'sults of the present study, alcuronium might be used cautiously in obstetrics when given in large doses or for a prolonged period, for example, to facilitate endotracheal intubation.
